Myriad Genetics (MYGN) Revenue & Revenue Breakdown
Myriad Genetics Revenue Highlights
Latest Revenue (Y)
$678.40M
Latest Revenue (Q)
$191.90M
Main Segment (Y)
Molecular Diagnostic Testing
Main Geography (Y)
UNITED STATES
Myriad Genetics Revenue by Period
Myriad Genetics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2022-12-31 | $678.40M | -1.77% |
| 2021-12-31 | $690.60M | 23.99% |
| 2020-12-31 | $557.00M | -34.56% |
| 2020-06-30 | $851.10M | - |
| 2019-06-30 | $851.10M | 10.16% |
| 2018-06-30 | $772.60M | 0.16% |
| 2017-06-30 | $771.40M | 2.33% |
| 2016-06-30 | $753.80M | 4.25% |
| 2015-06-30 | $723.10M | -7.08% |
| 2014-06-30 | $778.22M | 26.92% |
| 2013-06-30 | $613.16M | 23.62% |
| 2012-06-30 | $496.00M | 23.36% |
| 2011-06-30 | $402.08M | 10.87% |
| 2010-06-30 | $362.65M | 11.06% |
| 2009-06-30 | $326.53M | -2.13% |
| 2008-06-30 | $333.63M | 112.33% |
| 2007-06-30 | $157.13M | 37.49% |
| 2006-06-30 | $114.28M | 38.68% |
| 2005-06-30 | $82.41M | 45.47% |
| 2004-06-30 | $56.65M | -11.93% |
| 2003-06-30 | $64.32M | 19.47% |
| 2002-06-30 | $53.84M | 19.21% |
| 2001-06-30 | $45.16M | 32.78% |
| 2000-06-30 | $34.01M | 34.44% |
| 1999-06-30 | $25.30M | 9.05% |
| 1998-06-30 | $23.20M | 52.63% |
| 1997-06-30 | $15.20M | 130.30% |
| 1996-06-30 | $6.60M | - |
Myriad Genetics generated $678.40M in revenue during NA 2022, up -1.77% compared to the previous quarter, and up 87.81% compared to the same period a year ago.
Myriad Genetics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $191.90M | 4.58% |
| 2023-06-30 | $183.50M | 1.27% |
| 2023-03-31 | $181.20M | 1.91% |
| 2022-12-31 | $177.80M | 13.68% |
| 2022-09-30 | $156.40M | -12.77% |
| 2022-06-30 | $179.30M | 8.73% |
| 2022-03-31 | $164.90M | 2.55% |
| 2021-12-31 | $160.80M | -3.89% |
| 2021-09-30 | $167.30M | -11.67% |
| 2021-06-30 | $189.40M | 9.42% |
| 2021-03-31 | $173.10M | 11.97% |
| 2020-12-31 | $154.60M | 6.47% |
| 2020-09-30 | $145.20M | 55.79% |
| 2020-06-30 | $93.20M | -43.17% |
| 2020-03-31 | $164.00M | -15.94% |
| 2019-12-31 | $195.10M | 4.72% |
| 2019-09-30 | $186.30M | -13.51% |
| 2019-06-30 | $215.40M | -0.55% |
| 2019-03-31 | $216.60M | -0.09% |
| 2018-12-31 | $216.80M | 7.17% |
| 2018-09-30 | $202.30M | 0.70% |
| 2018-06-30 | $200.90M | 3.82% |
| 2018-03-31 | $193.50M | -0.26% |
| 2017-12-31 | $194.00M | 2.00% |
| 2017-09-30 | $190.20M | -5.14% |
| 2017-06-30 | $200.50M | 1.83% |
| 2017-03-31 | $196.90M | 0.20% |
| 2016-12-31 | $196.50M | 10.70% |
| 2016-09-30 | $177.50M | -4.83% |
| 2016-06-30 | $186.50M | -2.10% |
| 2016-03-31 | $190.50M | -1.45% |
| 2015-12-31 | $193.30M | 5.34% |
| 2015-09-30 | $183.50M | -3.36% |
| 2015-06-30 | $189.88M | 5.50% |
| 2015-03-31 | $179.99M | -2.39% |
| 2014-12-31 | $184.39M | 9.21% |
| 2014-09-30 | $168.84M | -10.56% |
| 2014-06-30 | $188.77M | 3.19% |
| 2014-03-31 | $182.92M | -10.36% |
| 2013-12-31 | $204.06M | 0.79% |
| 2013-09-30 | $202.47M | 16.28% |
| 2013-06-30 | $174.12M | 11.28% |
| 2013-03-31 | $156.47M | 4.92% |
| 2012-12-31 | $149.14M | 11.77% |
| 2012-09-30 | $133.44M | 0.35% |
| 2012-06-30 | $132.97M | 2.46% |
| 2012-03-31 | $129.78M | 5.67% |
| 2011-12-31 | $122.81M | 11.19% |
| 2011-09-30 | $110.45M | 2.83% |
| 2011-06-30 | $107.41M | 4.92% |
| 2011-03-31 | $102.37M | 1.93% |
| 2010-12-31 | $100.44M | 9.34% |
| 2010-09-30 | $91.86M | -2.20% |
| 2010-06-30 | $93.93M | 3.41% |
| 2010-03-31 | $90.83M | -2.09% |
| 2009-12-31 | $92.77M | 8.98% |
| 2009-09-30 | $85.12M | 5.07% |
| 2009-06-30 | $81.01M | -7.40% |
| 2009-03-31 | $87.49M | 3.69% |
| 2008-12-31 | $84.38M | 14.56% |
| 2008-09-30 | $73.65M | -55.86% |
| 2008-06-30 | $166.86M | 170.15% |
| 2008-03-31 | $61.77M | - |
Myriad Genetics generated $191.90M in revenue during Q3 2023, up 4.58% compared to the previous quarter, and up 107.03% compared to the same period a year ago.
Myriad Genetics Revenue Breakdown
Myriad Genetics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Jun 20 | Jun 19 | Jun 18 |
|---|---|---|---|
| Molecular Diagnostic Hereditary Cancer Testing | $347.40M | $479.70M | - |
| Molecular Diagnostic Other Testing | $14.40M | $8.00M | - |
| Molecular Diagnostic Prenatal Testing | $76.70M | $104.90M | - |
| Molecular Diagnostic Prolaris Testing | $24.70M | $25.50M | - |
| Molecular Diagnostic Testing | $586.90M | $789.40M | $719.30M |
| Molecular Diagnostic Vectra Testing | $39.10M | $48.30M | - |
| Pharmaceutical And Clinical Services | $51.70M | $61.70M | $53.30M |
| Molecular Diagnostic Endo Predict Testing | $10.50M | $10.40M | - |
| Molecular Diagnostic Genesight Testing | $74.10M | $112.60M | - |
Myriad Genetics's latest annual revenue breakdown by segment (product or service), as of Jun 20: Molecular Diagnostic Testing (47.89%), Molecular Diagnostic Hereditary Cancer Testing (28.35%), Molecular Diagnostic Prenatal Testing (6.26%), Molecular Diagnostic Genesight Testing (6.05%), Pharmaceutical And Clinical Services (4.22%), Molecular Diagnostic Vectra Testing (3.19%), Molecular Diagnostic Prolaris Testing (2.02%), Molecular Diagnostic Other Testing (1.18%), and Molecular Diagnostic Endo Predict Testing (0.86%).
Quarterly Revenue by Product
| Product/Service | Jun 23 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $8.70M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | $27.30M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Segments | - | $5.60M | $12.30M | $15.30M | $14.70M | - | - | - | - | - | - | - | - | - | - |
| Diagnostics | - | $161.70M | $177.10M | $157.80M | $130.50M | $150.50M | $177.60M | $170.40M | $200.50M | $203.00M | $189.00M | $179.70M | - | - | - |
| Molecular Diagnostic Genesight Testing | - | - | - | - | - | $8.50M | $29.80M | - | - | - | - | - | - | - | - |
| Molecular Diagnostic Other Testing | - | - | - | - | - | $4.30M | $1.70M | - | - | - | - | - | - | - | - |
| Pharmaceutical And Clinical Services | - | - | - | - | - | $9.90M | $18.50M | $13.30M | - | - | - | - | - | - | - |
| Molecular Diagnostic Vectra Testing | - | - | - | - | - | $7.30M | $12.20M | - | - | - | - | - | - | - | - |
| Molecular Diagnostic Testing | - | - | - | - | - | $83.30M | $196.90M | $187.60M | - | - | - | - | - | - | - |
| Molecular Diagnostic Prolaris Testing | - | - | - | - | - | $4.60M | $6.30M | - | - | - | - | - | - | - | - |
| Molecular Diagnostic Prenatal Testing | - | - | - | - | - | $16.60M | $24.90M | - | - | - | - | - | - | - | - |
| Molecular Diagnostic Endo Predict Testing | - | - | - | - | - | $2.20M | $3.00M | - | - | - | - | - | - | - | - |
| Molecular Diagnostic Hereditary Cancer Testing | - | - | - | - | - | $39.80M | $119.00M | - | - | - | - | - | - | - | - |
| All Other Segments | - | - | - | - | - | - | $13.50M | $17.50M | $15.90M | $16.10M | $13.80M | $13.30M | $13.80M | - | - |
Myriad Genetics's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: UNITED STATES (75.83%), and Non-US (24.17%).
Myriad Genetics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 |
|---|---|---|
| UNITED STATES | $84.50M | $24.20M |
| Non-US | $44.10M | $40.50M |
Myriad Genetics's latest annual revenue breakdown by geography, as of Dec 22: UNITED STATES (65.71%), and Non-US (34.29%).
Quarterly Revenue by Country
| Country | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Mar 20 | Dec 19 | Sep 19 | Mar 19 | Dec 18 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $19.70M | $8.70M | $8.50M | $20.80M | $10.60M | $12.00M | $12.80M | $10.00M | $11.50M | $11.10M | $3.60M | $200.00K | - | - | - | - | - | - |
| UNITED STATES | $172.20M | $27.30M | $28.80M | $157.00M | $20.20M | $21.50M | $19.70M | $16.50M | $21.40M | $10.70M | $13.50M | $9.50M | $153.00M | $182.30M | $174.70M | $204.40M | $205.80M | $191.60M |
| Non Us | - | - | - | - | - | - | - | - | - | - | - | - | $11.00M | $12.90M | $11.70M | $12.20M | $11.00M | $10.70M |
Myriad Genetics's latest quarterly revenue breakdown by geography, as of Sep 23: UNITED STATES (89.73%), and Non-US (10.27%).
Myriad Genetics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ILMN | Illumina | $4.50B | $1.08B |
| EXAS | Exact Sciences | $2.50B | $699.26M |
| QGEN | Qiagen | $1.97B | $458.80M |
| MEDP | Medpace | $1.89B | $528.10M |
| RDNT | RadNet | $1.62B | $459.71M |
| NTRA | Natera | $1.08B | $413.35M |
| SHC | Sotera Health Company | $1.05B | $276.59M |
| NEOG | Neogen | $924.22M | $228.81M |
| MYGN | Myriad Genetics | $678.40M | $191.90M |
| GH | Guardant Health | $563.95M | $177.24M |
| CDNA | CareDx | $280.32M | $92.27M |
| TWST | Twist Bioscience | $245.11M | $81.46M |
| CSTL | Castle Biosciences | $219.79M | $87.00M |
| OLK | Olink AB (publ) | $169.91M | $28.59M |
| PSNL | Personalis | $73.48M | $19.52M |
| ACRS | Aclaris Therapeutics | $31.25M | $2.40M |
MYGN Revenue FAQ
What is Myriad Genetics’s yearly revenue?
Myriad Genetics's yearly revenue for 2022 was $678.4M, representing a decrease of -1.77% compared to 2021. The company's yearly revenue for 2021 was $690.6M, representing an increase of 23.99% compared to 2020. MYGN's yearly revenue for 2020 was $557M, representing a decrease of -34.56% compared to 2019.
What is Myriad Genetics’s quarterly revenue?
Myriad Genetics's quarterly revenue for Q3 2023 was $191.9M, a 4.58% increase from the previous quarter (Q2 2023), and a 22.70% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $183.5M, a 1.27% increase from the previous quarter (Q1 2023), and a 2.34% increase year-over-year (Q2 2022). MYGN's quarterly revenue for Q1 2023 was $181.2M, a 1.91% increase from the previous quarter (Q4 2022), and a 9.88% increase year-over-year (Q1 2022).
What is Myriad Genetics’s revenue growth rate?
Myriad Genetics's revenue growth rate for the last 3 years (2020-2022) was 21.80%, and for the last 5 years (2018-2022) was -20.29%.
What are Myriad Genetics’s revenue streams?
Myriad Genetics's revenue streams in n 20 are Molecular Diagnostic Hereditary Cancer Testing, Molecular Diagnostic Other Testing, Molecular Diagnostic Prenatal Testing, Molecular Diagnostic Prolaris Testing, Molecular Diagnostic Testing, Molecular Diagnostic Vectra Testing, Pharmaceutical And Clinical Services, Molecular Diagnostic Endo Predict Testing, and Molecular Diagnostic Genesight Testing. Molecular Diagnostic Hereditary Cancer Testing generated $347.4M in revenue, accounting 28.35% of the company's total revenue, down -27.58% year-over-year. Molecular Diagnostic Other Testing generated $14.4M in revenue, accounting 1.18% of the company's total revenue, up 80.00% year-over-year. Molecular Diagnostic Prenatal Testing generated $76.7M in revenue, accounting 6.26% of the company's total revenue, down -26.88% year-over-year. Molecular Diagnostic Prolaris Testing generated $24.7M in revenue, accounting 2.02% of the company's total revenue, down -3.14% year-over-year. Molecular Diagnostic Testing generated $586.9M in revenue, accounting 47.89% of the company's total revenue, down -25.65% year-over-year. Molecular Diagnostic Vectra Testing generated $39.1M in revenue, accounting 3.19% of the company's total revenue, down -19.05% year-over-year. Pharmaceutical And Clinical Services generated $51.7M in revenue, accounting 4.22% of the company's total revenue, down -16.21% year-over-year. Molecular Diagnostic Endo Predict Testing generated $10.5M in revenue, accounting 0.86% of the company's total revenue, up 0.96% year-over-year. Molecular Diagnostic Genesight Testing generated $74.1M in revenue, accounting 6.05% of the company's total revenue, down -34.19% year-over-year.
What is Myriad Genetics’s main source of revenue?
For the fiscal year ending Jun 20, the largest source of revenue of Myriad Genetics was Molecular Diagnostic Testing. This segment made a revenue of $586.9M, representing 47.89% of the company's total revenue.